Anzeige
Mehr »
Freitag, 31.10.2025 - Börsentäglich über 12.000 News
Weltweiter Kaliboom treibt Nachfrage - ACM positioniert sich im 93,5 Mrd. USD-Markt bis 2032!!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0MSMZ | ISIN: US03152W1099 | Ticker-Symbol: AM6
Tradegate
30.10.25 | 20:21
7,750 Euro
+0,65 % +0,050
1-Jahres-Chart
AMICUS THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
AMICUS THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
7,6507,70030.10.
7,6007,80030.10.

Aktuelle News zur AMICUS THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
08.09.Amicus Therapeutics, Inc.: New 4-Year Data for Pombiliti (cipaglucosidase alfa-atga) + Opfolda (miglustat) Presented at ICIEM7
03.09.Amicus Therapeutics auf der Cantor Global: Zwischen starkem Wachstum und strategischen Herausforderungen5
AMICUS THERAPEUTICS Aktie jetzt für 0€ handeln
31.07.AMICUS THERAPEUTICS, INC. - 10-Q, Quarterly Report2
31.07.Amicus Therapeutics Non-GAAP EPS of $0.01 misses by $0.01, revenue of $154.7M beats by $8.02M6
31.07.Amicus Therapeutics, Inc.: Amicus Therapeutics Announces Second Quarter 2025 Financial Results and Corporate Updates227Q2 2025 Total Revenue of $154.7M, up 18% at CER Galafold® Q2 Revenue of $128.9M, up 12% at CER Pombiliti® + Opfolda® Q2 Revenue of $25.8M, up 58% at CER Reiterating 2025 Financial Guidance including...
► Artikel lesen
31.07.AMICUS THERAPEUTICS, INC. - 8-K, Current Report2
30.07.Amicus Therapeutics Q2 2025 Earnings Preview8
17.07.Amicus Therapeutics: Morgan Stanley stuft Aktie wegen starker Patentposition auf "Overweight" hoch36
17.07.Amicus Therapeutics stock upgraded to Overweight by Morgan Stanley on IP strength4
12.07.TD Cowen Remains Bullish on Amicus Therapeutics (FOLD) With a $20 PT5
10.06.Amicus Therapeutics bei Goldman Sachs Konferenz: Strategische Einblicke enthüllt7
05.06.AMICUS THERAPEUTICS, INC. - S-8, Securities to be offered to employees in employee benefit plans2
05.06.AMICUS THERAPEUTICS, INC. - 8-K, Current Report1
03.06.Amicus Therapeutics, Inc.: New Analysis of Pombiliti (cipaglucosidase alfa-atga) + Opfolda (miglustat) Published in Muscle and Nerve157PRINCETON, N.J., June 03, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced the publication of a post-hoc analysis of data from the ERT-experienced cohort of the PROPEL...
► Artikel lesen
01.05.Amicus Therapeutics, Inc.; Dimerix Limited: Dimerix and Amicus Therapeutics Announce Exclusive License Agreement for DMX-200 in the United States248Amicus licenses exclusive U.S. rights to commercialize DMX-200 for the treatmentof Focal Segmental Glomerulosclerosis (FSGS) DMX-200 is in a pivotal Phase 3 trial for FSGS, a rare and fatal kidney...
► Artikel lesen
19.02.Amicus Therapeutics, Inc.: Amicus Therapeutics Announces Full-Year 2024 Financial Results and Corporate Updates2512024 Total Revenue of $528.3M, a 33% Increase Year-over-Year Projecting 2025 Total Revenue Growth of 17-24% at CER Anticipate Achieving Positive GAAP Net Income During H2 2025 Conference Call and...
► Artikel lesen
30.01.Amicus Therapeutics UK Limited: Amicus Therapeutics Launches Amicus Ignite, a Proactive Community Funding Programme for Initiatives That Support People Living With Pompe Disease354Funding of up to €20,000 (or local currency equivalent), per application, for a limited number of projects is available to organisations and projects located outside of the United States. Projects...
► Artikel lesen
12.01.Amicus Therapeutics, Inc.: Amicus Therapeutics Reports Preliminary 2024 Revenue and Provides 2025 Strategic Outlook2162024 Total Revenue of $528M, Representing Significant Growth of 32% Year-Over-Year1 Strong and Growing Demand for Galafold® and Pombiliti® + Opfolda® Total Revenue Growth of 17-24% at CER Expected...
► Artikel lesen
18 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1